Zhitong Finance App News, Tiantan Biology (600161.SH) issued an announcement. Recently, “Human Coagulation Factor IX” developed by Chengdu Rongsheng Pharmaceutical Co., Ltd. (“Chengdu Rongsheng”), a subsidiary of the company, completed phase III clinical trials and obtained a clinical trial summary report.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.